Treatment Of Metastatic Squamous Non Small Cell

Share by Email The trial was closed for futility at the interim analysis. Adding ipilimumab to nivolumab did not improve survival in patients with advanced, previously treated, immunotherapy-naive squamous non-small cell lung cancer NSCLCaccording to phase 3 trial results published in JAMA Oncology.

Continue Reading The trial included eligible patients who had a mean age of The trial was terminated for futility at a planned interim analysis. The median follow-up in surviving patients was Overall survival OSthe primary endpoint, was similar between the treatment arms hazard ratio [HR], 0.

The median OS was 10 months for the nivolumab-ipilimumab arm and 11 months for the nivolumab-alone arm. Likewise, there was no significant difference in investigator-assessed progression-free survival PFS between the 2 arms HR, 0.

The median PFS was 3. The median duration of response was Grade 3 or higher treatment-related adverse events TRAEs occurred in Fatigue and pneumonitis were the most common grade 3 or higher TRAEs in both groups. There were 3 treatment-related deaths in the combination arm and 1 death in the monotherapy arm.

Please see the original reference for a full list of disclosures.]

Treatment Of Metastatic Squamous Non Small Cell Video

Metastatic Non Small Cell Lung Cancer

Treatment Of Metastatic Squamous Non Small Cell - sorry, that

Administered as 1-hr infusion every 3 wk. Administered every 3 wk for 4 cycles. Following chemotherapy, patients should receive radiotherapy. Precaution Monitor blood counts. Monitor patient for hypersensitivity, fluid retention, liver impairment, cardiac toxicity. Increased clearance of carboplatin. Potent CYP3A4 inhibitors eg, protease inhibitors eg, ritonavir, azole antifungals eg, ketoconazole or itraconazole. Food Interaction Avoid grapefruit products. Treatment Of Metastatic Squamous Non Small Cell.